MARKET

ONCO

ONCO

Onconetix
NASDAQ
1.060
-0.790
-42.70%
After Hours: 0.9580 -0.102 -9.62% 19:57 02/12 EST
OPEN
1.250
PREV CLOSE
1.850
HIGH
1.360
LOW
1.060
VOLUME
5.98M
TURNOVER
--
52 WEEK HIGH
54.39
52 WEEK LOW
1.060
MARKET CAP
1.65M
P/E (TTM)
-0.0030
1D
5D
1M
3M
1Y
5Y
1D
Onconetix Stock Plunges On Realbotix Acquisition
NASDAQ · 12h ago
BRIEF-Realbotix Corp. Announces The Sale Of Realbotix, Llc Subsidiary To A Nasdaq Listed Issuer
Reuters · 12h ago
Realbotix announces the sale of subsidiary to Onconetix
Seeking Alpha · 13h ago
Onconetix to acquire Realbotix LLC in all-stock transaction
TipRanks · 14h ago
Onconetix to Acquire Realbotix, Pivot to Humanoid AI
TipRanks · 14h ago
ONCO to Acquire Realbotix Subsidiary in All-Stock Deal
Reuters · 14h ago
Onconetix Acquires Realbotix in All-Stock Deal
Reuters · 14h ago
*Onconetix: Will Acquire 100% of the Issued and Outstanding Equity Interests of Realbotix in an all-Stk Transaction >ONCO
Dow Jones · 14h ago
More
About ONCO
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

Webull offers Onconetix Inc stock information, including NASDAQ: ONCO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCO stock methods without spending real money on the virtual paper trading platform.